AGP Picks
View all

Vivotif market seen growing through 2030 as typhoid cases rise

9 hours ago
Vivotif market seen growing through 2030 as typhoid cases rise
By AI, Created 14:45 UTC, Nov 19, 2026, AGP -

The Business Research Company says the global Vivotif market is positioned for steady growth from 2026 to 2030, driven by rising typhoid incidence, stronger vaccination efforts and higher healthcare spending. Asia-Pacific held the largest market share in 2025, according to the report.

Why it matters: - Rising typhoid fever cases and expanding preventive vaccination efforts are creating sustained demand for Vivotif, an oral vaccine used against typhoid fever. - The market outlook matters for travelers, endemic regions and public health programs trying to limit transmission and antibiotic resistance. - Download a free sample of the report for more detail.

What happened: - The Business Research Company released its Vivotif Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 19, 2026. - The report forecasts meaningful market developments from 2026 through 2030. - Vivotif is an oral vaccine approved for adults and children age 6 and older. - The vaccine is recommended for travelers to typhoid-endemic regions, people with close contact to carriers and laboratory professionals handling Salmonella typhi.

The details: - The report links market growth to increasing typhoid incidence and broader vaccination initiatives. - Historical growth was driven by more typhoid cases in endemic areas, more travel to high-risk destinations, government vaccination campaigns, oral vaccine availability and higher public awareness. - Forecast growth is expected to come from more preventive healthcare spending, stronger demand for travel vaccines, broader pediatric immunization programs, greater focus on antimicrobial resistance and better access in emerging markets. - The report highlights wider adoption of oral vaccination regimens, more proactive infectious disease management, improved cold-chain vaccine distribution and greater public understanding of typhoid prevention as key trends. - Typhoid fever spreads through contaminated food and water and can cause fever, abdominal pain and fatigue. - In August 2024, GOV.UK reported about 645 typhoid cases in England, Wales and Northern Ireland in 2023, up from 470 in 2022. - UK healthcare spending rose 5.6% from 2022 to 2023 to about $317.63 billion (£292 billion), according to the Office for National Statistics. - Asia-Pacific held the largest share of the Vivotif market in 2025. - The report also covers Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis, future trend analysis and updated graphics and tables. - View the full report for the complete forecast.

Between the lines: - The report frames Vivotif as a public-health product as much as a commercial market, tying demand to sanitation gaps, travel patterns and resistance concerns. - Asia-Pacific's market lead suggests the strongest need is concentrated in regions where typhoid exposure risk and preventive vaccination efforts overlap. - The emphasis on pediatric programs and emerging markets points to a wider push beyond traveler-only use.

What's next: - The market is expected to keep expanding through 2030 if typhoid incidence, travel vaccination demand and public-health investment continue rising. - Better vaccine access and improved distribution systems could support broader adoption in higher-risk markets. - The report's outlook suggests more attention to oral vaccination strategies and preventive care planning over the next several years.

The bottom line: - Vivotif's market is being pulled forward by a mix of disease burden, healthcare investment and global prevention efforts, with Asia-Pacific leading current demand.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

United Kingdom Political Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

United Kingdom Political Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.